Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
NTO-1151 by Ology Bioservices for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
NTO-1151 is under clinical development by Ology Bioservices and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to...
Data Insights
NTO-1151 by Ology Bioservices for Neuroendocrine Tumors: Likelihood of Approval
NTO-1151 is under clinical development by Ology Bioservices and currently in Phase II for Neuroendocrine Tumors. According to GlobalData, Phase...